Director Bienaime buys 1,000 (1.0K shares) KROS at $10.58 under 10b5-1 plan; stock -56.0% from 52-week high.
Director Jean Jacques Bienaime purchased 1,000 shares of Keros Therapeutics at $10.58 on 2026-05-15 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-05, meaning this was a scheduled transaction rather than a discretionary decision. The stock is currently trading at $9.91, -56.0% from its 52-week high of $22.55 and down 15.1% over the last 30 days. At this same ticker, Bienaime's two prior purchases (2026-04-15 and 2026-03-09) showed mixed results, with 30-day returns of -10.3% and +12.0% respectively. The company is unprofitable with a net loss of $-23,708,000.00 in the latest quarter against revenue of $32,000.00, and trades at a P/E of 4.24 on a market cap of $196,137,104.67. Since the transaction is scheduled under a 10b5-1 plan rather than discretionary, this purchase should be evaluated on plan mechanics and holdings context rather than as a signal of insider conviction.